Aagami is participating in JP Morgan Healthcare conference and Biotech Showcase January 2020 (13-16 January 2020 in San Francisco, CA). Both even...
Published : 02 Oct 2019
Read MoreAagami has been appointed by a new client to help out-license their on the market drug as well as other assets/ technologies in their extensive pipeli...
Published : 12 Sep 2019
Read MoreHappy Customers keep coming back. An Aagami client who gave us several assignments earlier has now engaged Aagami again for supporting his new startup...
Published : 26 Aug 2019
Read MoreAagami’s new client is focused on Bioremediation of Oil Field Contaminations. The company develops and manufactures products based on their patented...
Published : 20 Aug 2019
Read MoreIn keeping up with the its participatory tradition, Aagami is attending the 25th edition of the International Partnering Conference – BIO-...
Published : 11 Jul 2019
Read MoreA Belgium based synthetic biology specialist company developing original genetic technologies using bacteriocins has appointed Aagami to support out-l...
Published : 25 Jun 2019
Read MoreAagami will support out-licensing in India and selective other regions for an Israel based BioPharma Company with ‘Novel Treatment for Non-Surgical ...
Published : 03 Jun 2019
Read MoreAagami CEO, Dinesh Jain, is participating in the 2019 BIO International Convention which will be held in Philadelphia (June 3-6, 2019). This Annu...
Published : 15 May 2019
Read MoreOur new client is focused on transforming Lab innovations of India into market commercialization. Aagami has been selected to take such off...
Published : 01 Apr 2019
Read MoreOur new Korean client has developed E. coli Monophosphoryl Lipid A, a novel adjuvant. This is directly produced in genetically engineered E. coli and ...
Published : 05 Mar 2019
Read More